Generics 9

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Nintedanib manufacturers

9 products found

Filters

9 products found

nintedanib

Capsules 100 mg, 150 mg

Dossier type
US CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
FDA, EU GMP
Available for
Licensing with supply
Comments
Indication: Idiopathic Pulmonary Fibrosis; Status: MA granted (US), Ongoing Registration (EU)
Manufacturer #385

A pharmaceutical manufacturer based in the EU that has been active in 60+ countries selling its products in Europe, North America, LATAM, MENA, Africa, and Asia for 60+ years. Key production lines are Rx and nutraceuticals. The company's production lines are EU GMP-compliant.

Manufacturer usually replies in 10 days

nintedanib

Capsules 100 mg, 150 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Vietnam
Comments
MA's Granted
Manufacturer #21467

Manufacturer usually replies in 13 days

nintedanib

Oral suspension 50 mg/ml

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #31060

Manufacturer usually replies in nan days

Want to see all 9 products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription
Nintedanib is a medication used to treat idiopathic pulmonary fibrosis as well as in combination therapies for certain types of non-small-cell lung cancer. The nintedanib suppliers and distributors market it as 100mg and 150mg capsules. The developer and the sole nintedanib manufacturer is Boehringer Ingelheim, who acquired approval to market drug in 2014, under the trade name Ofev (in some countries – Vergatef). Ofev is currently approved in over 70 countries, and due to the ongoing validity of the supplier’s patent, other nintedanib manufacturers have yet to join the market with their formulations. Costs of nintedanib are relatively high and depend on the concentration of the active ingredient. The retail prices per 60 (100mg) capsules fall into an approximate range of 1,000 EUR to 1,200 EUR, whereas the same amount of 150mg capsules cost around 2,000 EUR to 2,250 EUR. Pharmaceutical specialists are welcome to browse through offers of nintedanib capsules for sale from nintedanib suppliers and distributors on our pharmaceutical marketplace, or else seek out further useful medical information about the medication online at the official Ofev website.

Interested in becoming a subscriber?

Please provide the following information to receive an offer tailored to your business needs

  1. Number of company users for the subscription
  2. The rough number of products you would like to source in the 12 months
  3. Target market(s) for commercialisation